Martina Tosi

Dr. Martina Tosi

Department of Health Sciences, Università del Piemonte Orientale, Via Solaroli 17, Novara, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Genes
Verified
Journal Article
Open access
PDF file
AMAlessandro Maglione
Alessandro Maglione
MZMIRIAM ZUCCALA'
MIRIAM ZUCCALA'
MTMartina Tosi
Martina Tosi
MCMarinella Clerico
Marinella Clerico
SRSimona Rolla
Simona Rolla
As a complex disease, Multiple Sclerosis (MS)’s etiology is determined by both genetic and environmental factors. In the last decade, the gut microbiome has emerged as an important environmental factor, but its interaction with host genetics is still unknown. In this review, we focus on these dual aspects of MS pathogenesis: we describe the current knowledge on genetic factors related to MS, based on genome-wide association studies, and then illustrate the interactions between the immune system, gut microbiome and central nervous system in MS, summarizing the evidence available from Experimental Autoimmune Encephalomyelitis mouse models and studies in patients. Finally, as the understanding of influence of host genetics on the gut microbiome composition in MS is in its infancy, we explore this issue based on the evidence currently available from other autoimmune diseases that share with MS the interplay of genetic with environmental factors (Inflammatory Bowel Disease, Rheumatoid Arthritis and Systemic Lupus Erythematosus), and discuss avenues for future research.

13 October 2021 in Genes
Verified
Journal Article
Open access
PDF file
NBNadia Barizzone
Nadia Barizzone
RCRachele Cagliani
Rachele Cagliani
CBChiara Basagni
Chiara Basagni
ECEMMA Clarelli
EMMA Clarelli
LMLaura Mendozzi
Laura Mendozzi
UDUmberto Dianzani
Umberto Dianzani
Known multiple sclerosis (MS) susceptibility variants can only explain half of the disease’s estimated heritability, whereas low-frequency and rare variants may partly account for the missing heritability. Thus, here we sought to determine the occurrence of rare functional variants in a large Italian MS multiplex family with five affected members. For this purpose, we combined linkage analysis and next-generation sequencing (NGS)-based whole exome and whole genome sequencing (WES and WGS, respectively). The genetic burden attributable to known common MS variants was also assessed by weighted genetic risk score (wGRS). We found a significantly higher burden of common variants in the affected family members compared to that observed among sporadic MS patients and healthy controls (HCs). We also identified 34 genes containing at least one low-frequency functional variant shared among all affected family members, showing a significant enrichment in genes involved in specific biological processes—particularly mRNA transport—or neurodegenerative diseases. Altogether, our findings point to a possible pathogenic role of different low-frequency functional MS variants belonging to shared pathways. We propose that these rare variants, together with other known common MS variants, may account for the high number of affected family members within this MS multiplex family.

2 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AAAnnamaria Annamaria
Annamaria Annamaria
MVMarco Varalda
Marco Varalda
KRKonkonika Roy
Konkonika Roy
FFFrancesco Favero
Francesco Favero
EMEleonora Mazzucco
Eleonora Mazzucco
Daniela CapelloDaniela Capello
Daniela Capello
Approximately 50% of colorectal cancer (CRC) patients still die from recurrence and metastatic disease, highlighting the need for novel therapeutic strategies. Drug repurposing is attracting increasing attention because, compared to traditional de novo drug discovery processes, it may reduce drug development periods and costs. Epidemiological and preclinical evidence support the antitumor activity of antipsychotic drugs. Herein, we dissect the mechanism of action of the typical antipsychotic spiperone in CRC. Spiperone can reduce the clonogenic potential of stem-like CRC cells (CRC-SCs) and induce cell cycle arrest and apoptosis, in both differentiated and CRC-SCs, at clinically relevant concentrations whose toxicity is negligible for non-neoplastic cells. Analysis of intracellular Ca2+ kinetics upon spiperone treatment revealed a massive phospholipase C (PLC)-dependent endoplasmic reticulum (ER) Ca2+ release, resulting in ER Ca2+ homeostasis disruption. RNA sequencing revealed unfolded protein response (UPR) activation, ER stress, and induction of apoptosis, along with IRE1-dependent decay of mRNA (RIDD) activation. Lipidomic analysis showed a significant alteration of lipid profile and, in particular, of sphingolipids. Damage to the Golgi apparatus was also observed. Our data suggest that spiperone can represent an effective drug in the treatment of CRC, and that ER stress induction, along with lipid metabolism alteration, represents effective druggable pathways in CRC.

3 July 2025 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
RGRoberto Gnavi
Roberto Gnavi
NBNadia Barizzone
Nadia Barizzone
RPRoberta Picariello
Roberta Picariello
PAPaolo Emilio Alboini
Paolo Emilio Alboini
NPNicola Pomella
Nicola Pomella
UDUmberto Dianzani
Umberto Dianzani
Background: Comorbidities are a critical concern for clinicians in both the treatment and diagnosis of multiple sclerosis. Autoimmune diseases, including multiple sclerosis, often co-occur within individuals. However, most studies examining the incidence or prevalence of autoimmune diseases in persons with multiple sclerosis compared to healthy controls have used relatively small sample sets, with only a few being population-based. Objectives: To analyze the co-occurrence of other autoimmune diseases in persons with multiple sclerosis and determine whether common genetic susceptibility factors contribute to the co-occurrence of autoimmune diseases. Methods: We conducted a population-based study using administrative health records to include all residents of Piedmont, an Italian Region with about 4.3 million inhabitants, identifying individuals with multiple sclerosis and 14 other autoimmune diseases. For a subset of persons with multiple sclerosis with available genome-wide genotyping data, we investigated the influence of their genetic backgrounds using a polygenic risk score. Results: The prevalence of all 14 tested autoimmune diseases was higher in persons with multiple sclerosis compared to those without multiple sclerosis. Furthermore, persons with multiple sclerosis with autoimmune disease comorbidities had a higher polygenic risk score compared to persons with multiple sclerosis without comorbidities. Conclusion: Our findings confirm the co-occurrence of multiple sclerosis with several autoimmune diseases, and suggest that shared genetic susceptibility factors may influence this association.

1 November 2026 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
ACAndrea Corona
Andrea Corona
MTMartina Tosi
Martina Tosi
AZAlen Zollo
Alen Zollo
NBNadia Barizzone
Nadia Barizzone
NPNicola Pomella
Nicola Pomella
FBfilippo martinelli boneschi
filippo martinelli boneschi
Background and ObjectivesPediatric-onset multiple sclerosis (PedMS) provides a unique opportunity to investigate MS pathogenesis because of the short interval between environmental exposures and di...

23 June 2025 in Cells
Verified
Journal Article
Open access
PDF file
CSChiara Sgromo
Chiara Sgromo
MTMartina Tosi
Martina Tosi
COCristina Olgasi
Cristina Olgasi
FMFabiola De Marchi
Fabiola De Marchi
FFFrancesco Favero
Francesco Favero
AFAntonia Follenzi
Antonia Follenzi
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease affecting motor neurons with a phenotypic and genetic heterogeneity and elusive molecular mechanisms. With the present pilot study, we investigated different genetic mutations (C9orf72, TARDBP, and KIF5A) associated with ALS by generating induced pluripotent stem cells (iPSCs) from peripheral blood of ALS patients and healthy donors. iPSCs showed the typical morphology, expressed stem cell markers both at RNA (OCT4, SOX2, KLF4, and c-Myc) and protein (Oct4, Sox2, SSEA3, and Tra1-60) levels. Moreover, embryoid bodies expressing the three germ-layer markers and neurospheres expressing neural progenitor markers were generated. Importantly, the transcriptomic profiles of iPSCs and neurospheres were analyzed to highlight the differences between ALS patients and healthy controls. Interestingly, the differentially expressed genes (DEGs) shared across all ALS iPSCs are linked to extracellular matrix, highlighting its importance in ALS progression. In contrast, ALS neurospheres displayed widespread deficits in neuronal pathways, although these DEGs were varied among patients, reflecting the disease’s heterogeneity. Overall, we generated iPSC lines from ALS patients with diverse genetic backgrounds offering a tool for unravelling the intricate molecular landscape of ALS, paving the way for identifying key pathways implicated in pathogenesis and the disease’s phenotypic variability.